22 April 2015 - Deborah Wilkes
Archived
Mylan has become the target of a US$40.1 billion hostile takeover proposal from Teva on the same day that Perrigo's board rejected a US$30.1 billion takeover proposal from Mylan.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.